Brokerages expect VERONA PHARMA P/S (NASDAQ:VRNA) to announce earnings of ($0.89) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for VERONA PHARMA P/S’s earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.64). VERONA PHARMA P/S reported earnings of ($0.23) per share in the same quarter last year, which indicates a negative year over year growth rate of 287%. The business is scheduled to issue its next earnings results on Tuesday, November 5th.
Zacks’ EPS averages are an average based on a survey of analysts that cover VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.27).
VRNA has been the topic of several recent research reports. ValuEngine raised shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Tuesday, July 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $58.00 target price on shares of VERONA PHARMA P/S in a research note on Monday, July 29th.
Shares of VRNA traded up $0.30 during midday trading on Thursday, reaching $4.60. The company had a trading volume of 5,600 shares, compared to its average volume of 6,861. VERONA PHARMA P/S has a 1-year low of $3.65 and a 1-year high of $14.50. The firm has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $5.52. The stock has a market cap of $59.25 million, a PE ratio of -2.28 and a beta of -1.00.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.